Login
From:
Neuromyelitis News
(Uncensored)
subscribe
NMOSD candidate therapy BAT4406F depletes B-cells, eases disability
https://neuromyelitisnews.com/news/nmosd-candidate-therapy-bat4406f-depletes-b-cells-eases-disability/
links
backlinks
Tagged with:
b-cells
nmosd
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.
Roast topics
Find topics
Find it!
